KRAS and neoplasm: However, the long-term prognosis of patients who receive selumetinib, as well as the late toxicity of the agent, have not yet been described.<h4>Case presentation</h4>In this case report, we present a patient with recurrent LGSOC with KRAS mutation whose tumor has not progressed and who has maintained a good general condition without severe toxicities following treatment with selumetinib for more than 7 years.